The role of cetuximab in the therapy of previously treated advanced colorectal cancer

被引:6
作者
Chong, G [1 ]
Cunningham, D [1 ]
机构
[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England
关键词
D O I
10.1053/j.seminoncol.2005.04.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S55 / S58
页数:4
相关论文
共 23 条
[1]  
[Anonymous], P AM SOC CLIN ONCOL
[2]  
BADARINATH S, 2004, P AN M AM SOC CLIN, V23, P253
[3]   Regulation of cell death protease caspase-9 by phosphorylation [J].
Cardone, MH ;
Roy, N ;
Stennicke, HR ;
Salvesen, GS ;
Franke, TF ;
Stanbridge, E ;
Frisch, S ;
Reed, JC .
SCIENCE, 1998, 282 (5392) :1318-1321
[4]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[5]   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery [J].
Datta, SR ;
Dudek, H ;
Tao, X ;
Masters, S ;
Fu, HA ;
Gotoh, Y ;
Greenberg, ME .
CELL, 1997, 91 (02) :231-241
[6]   Targeting the epidermal growth factor receptor [J].
El-Rayes, BF ;
LoRusso, PM .
BRITISH JOURNAL OF CANCER, 2004, 91 (03) :418-424
[7]   Insights into programmed cell death through structural biology [J].
Fesik, SW .
CELL, 2000, 103 (02) :273-282
[8]   Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells [J].
Konishi, A ;
Berk, BC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (37) :35049-35056
[9]  
LENZ HJ, 2004, P AN M AM SOC CLIN, V23, P248
[10]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139